Download Files:
Lazertinib
SKU
HY-109061-10 mg
Category Reference compound
Tags Cancer, EGFR, JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
$121 – $670
Products Details
Product Description
– Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer[1].
Web ID
– HY-109061
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C30H34N8O3
References
– [1]Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.
CAS Number
– 1903008-80-9
Molecular Weight
– 554.64
Compound Purity
– 99.73
SMILES
– C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 9 mg/mL (ultrasonic)
Target
– EGFR
Isoform
– EGFR/ErbB1/HER1
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.